AngioClast
Introductions
We are in the process of incorporating AngioClast as a company in Ireland. Our team has contacted the Irish registered address facility providers for quotes, prepared the constitution of the company and collected legal information of the team. In the last weeks, we also started to draft our license application. The task is crucial since the quality of our documentation will determine the time required to receive an approval. According to the information provided by the NIH, completion of the licensing process typically takes 6 to 12 months. A good and clear first application can reduce follow up questions and requests for additional information. Apart from the details of our team and company, the application for a license requires us to research if and to what extent the invention is already being used. Moreover, we will have to attach our R&D and marketing plan and include a detailed market analysis.
We are constantly developing our business plan. This includes updating our financial model to reflect the feedback we’ve received from the organizers as well as adding narrations to our financial model. In addition, the market analysis team performed a market analysis on the addressable market and competitors of the therapeutic product. We have also progressed far with our research in clinical trials, where we investigated the timeline and cost patterns of clinical trials. We achieved this through detailed analysis of annual reports of similar biotech startups. This gives us a better understanding to the current clinical trial climate.
We are expanding the AngioClasts’ network. We are actively reaching out to potential investors who would be interested in AngioClast, in particular, funders in the UK and US. We are also networking with potential stakeholders in CRO research, with a strong focus on CRO/CMOs that are in line with AngioClast’s strategy. We are seeking out for potential collaborators to develop a low cost but high diagnostic value ELISA based assay. Our initial focus would be in the US market, specifically researchers and oncologist in California. Furthermore, we have been meeting with industry experts to pick their brains on the trends in ADC based biotech sector.
We are constantly developing our business plan. This includes updating our financial model to reflect the feedback we’ve received from the organizers as well as adding narrations to our financial model. In addition, the market analysis team performed a market analysis on the addressable market and competitors of the therapeutic product. We have also progressed far with our research in clinical trials, where we investigated the timeline and cost patterns of clinical trials. We achieved this through detailed analysis of annual reports of similar biotech startups. This gives us a better understanding to the current clinical trial climate.
We are expanding the AngioClasts’ network. We are actively reaching out to potential investors who would be interested in AngioClast, in particular, funders in the UK and US. We are also networking with potential stakeholders in CRO research, with a strong focus on CRO/CMOs that are in line with AngioClast’s strategy. We are seeking out for potential collaborators to develop a low cost but high diagnostic value ELISA based assay. Our initial focus would be in the US market, specifically researchers and oncologist in California. Furthermore, we have been meeting with industry experts to pick their brains on the trends in ADC based biotech sector.